Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology

Executive Summary

• Defence Therapeutics announced that its Accum® platform dramatically improves the efficacy of ADCs, showing ~20‑fold higher anti‑tumor activity versus Kadcyla® alone in a HER2‑positive breast cancer mouse model.
• The company is actively pursuing partnerships to license the Accum® technology to other ADC developers, positioning itself as a supplier of next‑generation drug‑delivery solutions.
• Management highlighted the broader strategic intent to become an “ADC drug delivery powerhouse,” leveraging completed pre‑clinical studies that confirm potency and toxicity advantages.

Key Details

• Pre‑clinical efficacy: In mouse xenograft models (JIMT‑1 HER2‑positive breast cancer), Accum®‑Kadcyla at 0.5 mg/kg achieved ~20× greater anti‑tumor effect than Kadcyla® alone, halting tumor growth and producing near‑complete responses in 90% of treated mice.
• Technology positioning: Accum® can be applied to any antibody‑drug conjugate, aiming to reduce toxicity while preserving epitope selectivity and tumor targeting across indications.
• Business development: Defence is engaging ADC companies worldwide (e.g., contacts made at the World ADC Conference in San Diego and CPHI in Frankfurt) to license or co‑develop products using the Accum® platform.
• Strategic goal: Transform into a supplier of proprietary ADC delivery technology, expanding beyond internal product pipelines to create an “ADC drug delivery powerhouse.”
• Leadership comment: Dr. Maxime Parisotto (Chief Scientific Officer) emphasized that many biotech firms face toxicity challenges with ADCs and that Accum® offers a universal potency‑enhancing solution.

Notable Quotes

“Many pharmaceuticals and biotech companies have ADCs on the market or in development… Defence's Accum® technology can universally enhance the potency of any ADCs, reducing their toxicity, while retaining their epitope selectivity and tumor targeting,” – Dr. Maxime Parisotto, Chief Scientific Officer.